CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 198 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04079920
NCT04079920N/ACompleted

BASELINE VARIABLES PREDICTING TREATMENT RESPONSE AT 6 MONTHS IN ADULT RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB 5MG BID IN A NON-INTERVENTIONAL SETTING (TREAT - RA)

Pfizer·observational·Posted Sep 6, 2019·Updated Jun 8, 2025

In Brief

An observational study for Rheumatoid Arthritis. Completed, enrolled 198 participants across 18 sites.

Detailed Summary

This is a 24-month, prospective, non-interventional, multi-center study with primary aim to identify baseline characteristics of patients that predict response at 6 months of treatment. The study also aims to describe the treatment patterns of RA patients prescribed tofacitinib in a real-world setting and assess the effect of treatment on patient quality of life and physical function. Finally the study will assess the use of healthcare resources and costs in patients with RA treated with tofacitinib in Greece. The planned recruitment period is 12 months. The planned observation period of each patient is 12 months. In this time period up to 4 visits will be documented. The study will be reviewed and approved by the Central Regulatory Committee for NIS and IRB Board of each participating site

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesGreece
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedSep 6, 2019
Enrollment StartSep 22, 2020
Primary CompletionFeb 8, 2023
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 6.8 years ago